To print this article, all you need is to be registered or login on Mondaq.com.
The Chinese National Intellectual Property Administration
(CNIPA) has established a two-year pilot cooperation with the
European Patent Office (EPO) for patent applications filed under
the Patent Cooperation Treaty (PCT).
With effect from 1
st December 2020, nationals and
residents of the People s Republic of China including its
Special Administrative Regions Hong Kong and Macau are allowed to
designate EPO, other than CNIPA, as their International Searching
Authority (ISA) and International Preliminary Examining Authority
(IPEA) for international applications filed in English under the
PCT. This pilot cooperation is available to 2500 applications in
Screenshot: WB Games
After trying multiple times since 2015, WB Games has successfully secured a patent on the nemesis system featured in Shadow of Mordor and its sequel,
Shadow of War. The patent goes into effect later this month.
Advertisement
As reported by IGN, on February 3 the US Patent and Trademark Office released an issue notice confirming that WB Games’ patent on the system was approved and would become effective officially on February 23, 2021.
(That issue notice link wasn’t working at the time of publication.)
The nemesis system first appeared in 2014 s open-world-stab-athon
Shadow of Mordor, and would be expanded on greatly in the 2017 sequel
To print this article, all you need is to be registered or login on Mondaq.com.
In order to encourage the development of innovative
pharmaceutical companies in China, patent term extension (PTE) is
introduced for the first time to the amended Chinese Patent Law
that will take effect from June 1, 2021.
PTE was first introduced from the Hatch-Waxman act of the U.S in
1984, with the aim to make up for the time taken for the clinical
trials and market approval of a drug. At the beginning of 2020, PTE
was mentioned in the Economic and Trade Agreement Between China and
the U.S, and then was added to Article 42 of the new Chinese Patent
Canadian Patent No. 2,461,202 (the
202
Patent), which was asserted by Bristol-Myers Squibb Canada
Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company
(collectively,
BMS). The 202 Patent claims
the active ingredient apixaban and its use for the treatment and
prevention of thromboembolic disorders (blood clots).
Canadian Patent No. 2,791,171 (the
171
Patent), which was asserted by BMS and Pfizer Inc.
(collectively,
BMS & Pfizer). The 171
Patent claims tablet formulations of apixaban.
The Defendants only non-infringement allegation was that
the asserted claims of each of the patents were invalid.
The 202 Patent: compound and use claims valid and
infringed
Construction. The sole issue with respect
to construction of the asserted claims of the 202 Patent was